STOCK TITAN
  1. Home
  2. Sec-filings
  3. ORIC
  4. [Form 4] Oric Pharmaceuticals, Inc. Insider Trading Activity

Chacko Jacob disposes 37,461 ORIC shares under 10b5-1 plan

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Oric Pharmaceuticals director and CEO Chacko Jacob reported the sale of 37,461 shares of ORIC common stock on 10/06/2025. The filing shows the shares were sold under a Rule 10b5-1 trading plan adopted on 06/21/2025 at a weighted average price of $12.32 (range $12.07–$12.59). After the reported sale, the reporting person beneficially owned 531,419 shares directly; the filing separately discloses 178,667 RSUs and 3,378,000 stock options previously reported on Table II and not included in that total. The Form 4 was signed by an attorney-in-fact on 10/08/2025.

Positive

  • Sale executed under a Rule 10b5-1 plan, indicating pre-planned trading actions
  • Reporting person retains substantial direct ownership of 531,419 shares after the sale
  • Additional equity exposure disclosed: 178,667 RSUs and 3,378,000 stock options remain outstanding

Negative

  • Insider disposed of 37,461 shares, which may be viewed negatively by some investors despite the 10b5-1 plan
  • Weighted average sale price was $12.32, reflecting realized proceeds at current market levels

Insights

Insider sale executed under a documented 10b5-1 plan; ownership remains substantial.

The reported sale of 37,461 shares at a weighted average price of $12.32 was effected pursuant to a Rule 10b5-1 trading plan adopted on 06/21/2025, which provides an affirmative defense against insider-trading claims when properly implemented.

Post-sale direct ownership is 531,419 shares, with additional economic exposure from 178,667 RSUs and 3,378,000 options previously reported. Watch for any future filings that change the size of option or RSU holdings or disclose additional 10b5-1 plan terms within the next reporting cycle.

Insider Chacko Jacob
Role PRESIDENT AND CEO
Sold 37,461 shs ($462K)
Type Security Shares Price Value
Sale Common Stock 37,461 $12.32 $462K
Holdings After Transaction: Common Stock — 531,419 shares (Direct)
Footnotes (1)
  1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2025. Represents the weighted average share price of an aggregate total of 37,461 shares sold in the price range of $12.07 to $12.59 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. The Reporting Person also holds restricted stock units (RSUs) representing a contingent right to receive 178,667 shares of ORIC Pharmaceuticals, Inc. Common Stock and stock options to purchase 3,378,000 shares of ORIC Pharmaceuticals, Inc. Common Stock, which were previously reported on Table II and are not included in this number.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Chacko Jacob
(Last) (First) (Middle)
C/O ORIC PHARMACEUTICALS, INC.
240 E. GRAND AVE., 2ND FLOOR
(Street)
SOUTH SAN FRANCISCO CA 94080
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Oric Pharmaceuticals, Inc. [ ORIC ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
PRESIDENT AND CEO
3. Date of Earliest Transaction (Month/Day/Year)
10/06/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/06/2025 S(1) 37,461 D $12.32(2) 531,419(3) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2025.
2. Represents the weighted average share price of an aggregate total of 37,461 shares sold in the price range of $12.07 to $12.59 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
3. The Reporting Person also holds restricted stock units (RSUs) representing a contingent right to receive 178,667 shares of ORIC Pharmaceuticals, Inc. Common Stock and stock options to purchase 3,378,000 shares of ORIC Pharmaceuticals, Inc. Common Stock, which were previously reported on Table II and are not included in this number.
/s/ Christian Kuhlen, attorney-in-fact 10/08/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did ORIC insider Chacko Jacob report on Form 4?

He sold 37,461 shares on 10/06/2025 under a Rule 10b5-1 plan at a weighted average price of $12.32.

Was the sale by the ORIC reporting person part of a planned trading program?

Yes. The Form 4 states the sales were made under a Rule 10b5-1 trading plan adopted on 06/21/2025.

How many ORIC shares does the reporting person own after the sale?

531,419 shares of common stock are reported as beneficially owned directly following the transaction.

Does the reporting person hold other equity awards in ORIC?

Yes. The filing discloses 178,667 RSUs and 3,378,000 stock options previously reported on Table II and excluded from the direct-ownership total.

When was the Form 4 signed and filed?

The Form 4 bears a signature by attorney-in-fact on 10/08/2025.